Quarterly ResultMay 12, 2026, 05:05 PM
BridgeBio Oncology Reports Encouraging Clinical Data; Cash Runway into 2028
AI Summary
BridgeBio Oncology Therapeutics reported encouraging preliminary safety and efficacy data across all three of its RAS-pathway inhibitor programs, BBO-8520, BBO-11818, and BBO-10203, with clinical readouts expected in the second half of 2026. The company also announced Q1 2026 financial results, including a net loss of $42.1 million, and confirmed a cash runway into 2028 with $388.9 million in cash. Additionally, key management changes were announced, including a new CEO and COO.
Key Highlights
- BBO-8520 showed 65% objective response rate and 68% 6-month progression-free survival in KRASG12C NSCLC.
- BBO-11818 achieved a partial response with 56% tumor reduction in pancreatic cancer.
- Cash, cash equivalents, and marketable securities totaled $388.9 million as of March 31, 2026.
- Cash runway is expected to fund operations into 2028.
- Q1 2026 R&D expenses increased to $39.8 million from $20.6 million year-over-year.
- Q1 2026 net loss was $42.1 million, up from $22.1 million year-over-year.
- Pedro J. Beltran was appointed CEO and Idan Elmelech COO, effective April 20, 2026.